Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
Delayed Swiss Exchange  -  11:30 2022-09-29 am EDT
38.15 CHF   -0.39%
09/26Basilea Pharmaceutica : Updated September 26, 2022
PU
09/21SillaJen Bags Licensing Right to Basilea Pharmaceutica's Oncology Drug
MT
09/21Basilea Pharmaceutica Secures $78 Million Senior Secured Loan From Athyrium Capital
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea to Suspend Studies For Lisavanbulin, End Derazantinib Licensing Deal With Merck & Co

06/27/2022 | 01:59am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BASILEA PHARMACEUTICA AG -0.39% 38.15 Delayed Quote.-6.40%
MERCK & CO., INC. -0.12% 86.58 Delayed Quote.13.23%
All news about BASILEA PHARMACEUTICA AG
09/26Basilea Pharmaceutica : Updated September 26, 2022
PU
09/21SillaJen Bags Licensing Right to Basilea Pharmaceutica's Oncology Drug
MT
09/21Basilea Pharmaceutica Secures $78 Million Senior Secured Loan From Athyrium Capital
MT
09/21Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
GL
09/21Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
DJ
09/20Basilea Pharmaceutica Boosts FY22 Revenue Outlook After Disposal Deal For Oncology Asse..
MT
09/20Basilea Pharmaceutica Sells Oncology Asset Rights To South Korea's SillaJen
MT
09/20Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and upda..
GL
09/20Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and upda..
DJ
09/20Basilea Pharmaceutica AG Enters into Asset Purchase Agreement and Sub-License Agreement..
CI
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2022 111 M 113 M 113 M
Net income 2022 -23,0 M -23,5 M -23,5 M
Net Debt 2022 90,0 M 91,8 M 91,8 M
P/E ratio 2022 -19,1x
Yield 2022 -
Capitalization 454 M 463 M 463 M
EV / Sales 2022 4,90x
EV / Sales 2023 3,68x
Nbr of Employees 177
Free-Float 88,1%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 38,30 CHF
Average target price 73,98 CHF
Spread / Average Target 93,2%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Head-Corporate Development
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Head-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG-6.40%463
MODERNA, INC.-51.91%47 785
LONZA GROUP AG-37.97%35 765
IQVIA HOLDINGS INC.-34.19%34 633
SEAGEN INC.-10.92%25 400
ALNYLAM PHARMACEUTICALS, INC.19.48%25 297